MAG 2 20CPR EFF 2,25G

MAG2 2,25 G COMPRESSE EFFERENCES

active ingredients

An effervescent tablet contains: active ingredient: magnesium pidolato 2,25O g (corresponding to 184 mg of ion Mg^{+ +}). Excipients with known effects: sorbitol and sodium. For the full list of excipients, see section 6.1.

Excellent

Citric acid anidro, sodium bicarbonate, sorbitol, sodium carbonate anidro, lemon aroma, orange aroma, potassium acesulfame, anidra colloidal silica.

Therapeutic indications

Magnesium deficiency states.

Contraindications

Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1. Severe kidney failure (cancer of creatine less than 30 mL/min). Not to be administered in subjects subjected to digital therapy.

Population

Population Only for adults: 2 tablets per day. Pediatric population In children, posology may be established by the doctor after consultation. Caution: use only for short periods of treatment. Instructions for use Dissolve an effervescent tablet in water.

Conservation

Store in the original packaging to protect the medicine from moisture.

Warnings

In case of concomitant calcium deficiency, magnesium deficiency must be corrected before administering additional calcium. In patients with moderate kidney failure, it is necessary to reduce posology and monitor kidney function and magnesemia, due to the risk associated with hypermagnesemia. It is appropriate to consider the possibility that in course of treatment there is depression of cardiovascular activity MAG2 contains • sorbitol: patients with hereditary intolerance to fructose should not be given this medicine; • sodio: this medicine contains about 513 mg of sodium per effervescent tablet, equivalent to 26% of the maximum daily intake recommended by the WHO which corresponds to 2 g sodium for an adult. To be considered in people with reduced kidney function or following a low sodium diet.

Interactions

In case of oral tetracycline treatment, the administration of MAG2 must be delayed by at least 3 hours. Chinolones should be administered at least 2 hours before or 6 hours after the administration of magnesium-based products to avoid interference with their absorption. Concurrent administration of magnesium and cholecalciferol products (vitamin D3) may lead to the appearance of hypercalcemia. We do not recommend the concomitant use of preparations containing calcium salts or phosphate since such products prevent intestinal absorption of magnesium. The simultaneous intake of magnesium-based products with depressing drugs the Central Nervous System can enhance the effects on the magnesium SNC and should be carefully evaluated.

Effects

The following Convention has been used for the classification of unwanted effects: very common ≥ 1/10; common ≥ 1/100 and gastrointestinal diseases: Frequency not known: gastrointestinal disorders, diarrhea, abdominal pain. Pathologies of skin and subcutaneous tissue: Frequency not known: skin reactions. Immune system disorders: Frequency not known: hypersensitivity. Exceptional cases of individual intolerance to magnesium have been reported, which can be treated with oral or parental antihistamines. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/web/guest/content/segnalazioni-reazioni- adverse.

Overdosing

Signs and symptoms Overdose of oral magnesium does not generally induce toxic reactions in the presence of normal kidney function. Magnesium poisoning can however develop in case of severe kidney failure. The toxic effect depends mainly on the serum levels of magnesium and the signs are as follows: decrease in blood pressure, nausea, vomiting, depression of the Central Nervous System, decrease in reflections, abnormalities in the ECG (e.g. heart rhythm disorders), occurrence of respiratory depression, coma, cardiac arrest, respiratory paralysis, anurian syndrome and neuromuscular transmission disorders. Therapy Treatment should include rehydration with restoration of a plentiful diuresis or forced diuresis. In the presence of kidney failure, hemodialysis or peritoneal dialysis is necessary.

Limited data are available on the use of MAG2 in pregnant women. However, it is not possible to draw conclusions that the use of MAG2 is safe during pregnancy. MAG2 can only be used during pregnancy if potential benefits for the mother exceed potential risks, including those for the fetus. Magnesium is considered compatible with breastfeeding.

Source: Farmadati